Despite winning the six Xarelto (rivaroxaban) product liability cases that went to trial, Bayer AG and Johnson & Johnson have decided to settle all ongoing litigation for $775m.
The co-marketers of Xarelto had been determined to avoid the path of Boehringer Ingelheim GmbH, which settled similar litigation...





